颖泰生物
(833819)
| 流通市值：53.03亿 | | | 总市值：53.81亿 |
| 流通股本：12.08亿 | | | 总股本：12.26亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,327,541,477.66 | 2,878,968,888.16 | 1,374,078,857.91 | 5,868,305,351.83 |
| 营业收入 | 4,327,541,477.66 | 2,878,968,888.16 | 1,374,078,857.91 | 5,868,305,351.83 |
| 二、营业总成本 | 4,453,921,595.05 | 2,911,718,084.59 | 1,400,108,915.88 | 5,646,981,763.18 |
| 营业成本 | 3,832,421,869.75 | 2,520,302,752.31 | 1,207,431,189.61 | 4,863,913,295.04 |
| 税金及附加 | 24,375,034.53 | 15,522,078.36 | 7,941,159.13 | 32,527,355.4 |
| 销售费用 | 61,708,849.01 | 42,560,381.07 | 17,825,104.12 | 99,781,586.38 |
| 管理费用 | 277,122,483.91 | 182,419,664.78 | 92,501,130.18 | 363,365,088.74 |
| 研发费用 | 129,541,520.16 | 85,066,760.84 | 38,485,848.65 | 166,540,895.64 |
| 财务费用 | 128,751,837.69 | 65,846,447.23 | 35,924,484.19 | 120,853,541.98 |
| 其中:利息费用 | 135,596,553.03 | 90,959,706.43 | 43,726,074.16 | 184,351,298.64 |
| 其中:利息收入 | 15,231,854.02 | 11,344,758.33 | 5,428,015.77 | 33,694,377.81 |
| 加:公允价值变动收益 | -586,961.84 | -1,186,596.58 | -747,635.04 | -802,444.18 |
| 加:投资收益 | -93,416,079.84 | -42,589,922.63 | -3,193,953.22 | -70,571,926.79 |
| 资产处置收益 | 4,085,095.09 | 3,636,501.14 | 192,168.54 | 21,883,529.25 |
| 资产减值损失(新) | -16,222,420.95 | -13,489,686 | -52,112.44 | -87,258,225.06 |
| 信用减值损失(新) | 129,377.27 | -1,690,187.02 | -301,827.41 | 13,233,146.5 |
| 其他收益 | 27,668,529.37 | 14,340,759.24 | 5,282,301.1 | 68,928,803.25 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -204,722,578.29 | -73,728,328.28 | -24,851,116.44 | 166,736,471.62 |
| 加:营业外收入 | 2,480,522.71 | 1,754,269.43 | 1,436,845.64 | 8,051,218.01 |
| 减:营业外支出 | 5,575,752.91 | 3,792,534.05 | 1,965,005.39 | 11,568,939.96 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -207,817,808.49 | -75,766,592.9 | -25,379,276.19 | 163,218,749.67 |
| 减:所得税费用 | -4,263,159.72 | 6,856,261.2 | 5,983,243.93 | 72,044,510.73 |
| 六、净利润 | -203,554,648.77 | -82,622,854.1 | -31,362,520.12 | 91,174,238.94 |
| 持续经营净利润 | -203,554,648.77 | -82,622,854.1 | -31,362,520.12 | 91,174,238.94 |
| 归属于母公司股东的净利润 | -198,170,380.37 | -79,384,075.67 | -29,764,161.3 | 95,683,463.98 |
| 少数股东损益 | -5,384,268.4 | -3,238,778.43 | -1,598,358.82 | -4,509,225.04 |
| (一)基本每股收益 | -0.16 | -0.06 | -0.02 | 0.08 |
| (二)稀释每股收益 | -0.16 | -0.06 | -0.02 | 0.08 |
| 八、其他综合收益 | -69,466,208.68 | -31,810,978.22 | -8,113,453.1 | 19,036,007.53 |
| 归属于母公司股东的其他综合收益 | -69,466,208.68 | -31,810,978.22 | -8,113,453.1 | 19,036,007.53 |
| 九、综合收益总额 | -273,020,857.45 | -114,433,832.32 | -39,475,973.22 | 110,210,246.47 |
| 归属于母公司股东的综合收益总额 | -267,636,589.05 | -111,195,053.89 | -37,877,614.4 | 114,719,471.51 |
| 归属于少数股东的综合收益总额 | -5,384,268.4 | -3,238,778.43 | -1,598,358.82 | -4,509,225.04 |
| 公告日期 | 2024-10-25 | 2024-08-19 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |